These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34440251)

  • 1. Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?
    van Oost S; Meijer DM; Kuijjer ML; Bovée JVMG; de Miranda NFCC
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for sarcomas.
    Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T
    Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities.
    Jeong S; Afroz S; Kang D; Noh J; Suh J; Kim JH; You HJ; Kang HG; Kim YJ; Kim JH
    Mol Cells; 2023 Oct; 46(10):579-588. PubMed ID: 37853684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
    Nathenson MJ; Conley AP; Sausville E
    Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?
    Chew HY; Chan V; Simpson F; Dolcetti R
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33207697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Immunotherapy in Sarcomas.
    Dalal S; Shan KS; Thaw Dar NN; Hussein A; Ergle A
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging trends in immunotherapy for pediatric sarcomas.
    Dyson KA; Stover BD; Grippin A; Mendez-Gomez HR; Lagmay J; Mitchell DA; Sayour EJ
    J Hematol Oncol; 2019 Jul; 12(1):78. PubMed ID: 31311607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy?
    Atherton MJ; Lenz JA; Mason NJ
    Vet Comp Oncol; 2020 Dec; 18(4):447-470. PubMed ID: 32246517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.
    Zhu MMT; Shenasa E; Nielsen TO
    Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1, PD-L1, IDO, CD70 and microsatellite instability as potential targets to prevent immune evasion in sarcomas.
    Siozopoulou V; Smits E; Zwaenepoel K; Liu J; Pouliakis A; Pauwels PA; Marcq E
    Immunotherapy; 2023 Oct; 15(15):1257-1273. PubMed ID: 37661910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knowing the myeloid-derived suppressor cells: Another enemy of sarcomas patients.
    García-Domínguez DJ; Sánchez-Margalet V; de la Cruz-Merino L; Hontecillas-Prieto L
    Int Rev Cell Mol Biol; 2023; 375():93-116. PubMed ID: 36967155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapeutic strategies for sarcoma: current perspectives.
    Li X; Wang G; Cai Z; Sun W
    Am J Transl Res; 2020; 12(12):7693-7701. PubMed ID: 33437354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Landscape of Immunotherapy for Retroperitoneal Sarcoma.
    Gingrich AA; Nassif EF; Roland CL; Keung EZ
    Curr Oncol; 2023 Feb; 30(2):2144-2158. PubMed ID: 36826126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy.
    Efremova M; Finotello F; Rieder D; Trajanoski Z
    Front Immunol; 2017; 8():1679. PubMed ID: 29234329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials.
    Tang F; Tie Y; Wei YQ; Tu CQ; Wei XW
    Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188606. PubMed ID: 34371128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging Trends in Immunotherapy for Adult Sarcomas.
    Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
    Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From vision to reality: deploying the immune system for treatment of sarcoma.
    Wilky BA; Goldberg JM
    Discov Med; 2017 Jan; 23(124):61-74. PubMed ID: 28245428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
    Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments.
    Ngo C; Postel-Vinay S
    Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.